A phase 2 study of high-activity 186Re-HEDP with autologous peripheral blood stem cell transplant in progressive hormone-refractory prostate cancer metastatic to bone

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 33, Issue 9, 2006, Pages 1055-1061

  O'Sullivan, J M ^a   Norman, A R ^b   McCready, V R ^b   Flux, G ^b   Buffa, F M ^b   Johnson, B ^b   Coffey, J ^b   Cook, G ^b   Treleaven, J ^b   Horwich, A ^b   Huddart, R A ^b   Parker, C C ^b   Dearnaley, D P ^b  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Bone metastases; Palliation; Prostate cancer; Radionuclide therapy; Stem cell transplantation

Indexed keywords

ETIDRONIC ACID RE 186; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANEMIA; ARTICLE; AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; BLOOD TOXICITY; BONE METASTASIS; CANCER CONTROL; CLINICAL ARTICLE; CLINICAL TRIAL; DISEASE COURSE; HORMONE REFRACTORY PROSTATE CANCER; HUMAN; KAPLAN MEIER METHOD; LEUKOPENIA; MALE; NEUTROPENIA; PAIN ASSESSMENT; PERFORMANCE; PHASE 2 CLINICAL TRIAL; PROSTATE CANCER; QUALITY OF LIFE; RADIOISOTOPE THERAPY; RESPONSE VARIABLE; SEPSIS; SOFT TISSUE DISEASE; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT RESPONSE;

AGED; BONE NEOPLASMS; COMBINED MODALITY THERAPY; DRUG RESISTANCE, NEOPLASM; ETIDRONIC ACID; HUMANS; MALE; MIDDLE AGED; ORGANOMETALLIC COMPOUNDS; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PROSTATIC NEOPLASMS; RADIOISOTOPES; RADIOPHARMACEUTICALS; RHENIUM; TRANSPLANTATION, AUTOLOGOUS;

EID: 33747039548     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-005-0010-5     Document Type: Article

References (35)

1. Clarke NW. The management of hormone-relapsed prostate cancer. BJU Int 2003;92(8):860-868
2. Dearnaley DP. Cancer of the prostate. BMJ 1994;308(6931):780-784
3. Pisters LL. The challenge of locally advanced prostate cancer. Semin Oncol 1999;26(2):202-216
4. Tannock IF, Osoba D, Stockler MR, Ernst DS, Neville AJ, Moore MJ, et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 1996;14(6):1756-1764
5. Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004;351(15):1513-1520
6. Sridhara R, Eisenberger MA, Sinibaldi VJ, Reyno LM, Egorin MJ. Evaluation of prostate-specific antigen as a surrogate marker for response of hormone-refractory prostate cancer to suramin therapy. J Clin Oncol 1995;13(12):2944-2953
7. Fossa SD, Slee PH, Brausi M, Horenblas S, Hall RR, Hetherington JW, et al. Flutamide versus prednisone in patients with prostate cancer symptomatically progressing after androgen-ablative therapy: a phase III study of the European organization for research and treatment of cancer genitourinary group. J Clin Oncol 2001;19(1):62-71
8. Kelly WK, Scher HI, Mazumdar M, Vlamis V, Schwartz M, Fossa SD. Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer. J Clin Oncol 1993;11(4):607-615
9. Small EJ, Vogelzang NJ. Second-line hormonal therapy for advanced prostate cancer: a shifting paradigm. J Clin Oncol 1997;15(1):382-388
10. Lewington VJ, McEwan AJ, Ackery DM, Bayly RJ, Keeling DH, Macleod PM, et al. A prospective, randomised double-blind crossover study to examine the efficacy of strontium-89 in pain palliation in patients with advanced prostate cancer metastatic to bone. Eur J Cancer 1991;27(8):954-958
11. Porter AT, McEwan AJ, Powe JE, Reid R, McGowan DG, Lukka H, et al. Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer. Int J Radiat Oncol Biol Phys 1993;25(5):805-813
12. Quilty PM, Kirk D, Bolger JJ, Dearnaley DP, Lewington VJ, Mason MD, et al. A comparison of the palliative effects of strontium-89 and external beam radiotherapy in metastatic prostate cancer. Radiother Oncol 1994;31(1):33-40
13. Serafini AN, Houston SJ, Resche I, Quick DP, Grund FM, Ell PJ, et al. Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam: a double-blind placebo-controlled clinical trial. J Clin Oncol 1998;16(4):1574-1581
14. 186Re-etidronate in hormone-resistant prostate cancer patients with painful bone metastases. Placebo Controlled Rhenium Study. J Nucl Med 2002;43(9):1150-1156
15. Tu SM, Millikan RE, Mengistu B, Delpassand ES, Amato RJ, Pagliaro LC, et al. Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial. Lancet 2001;357(9253):336-341
16. Palmedo H, Manka-Waluch A, Albers P, Schmidt-Wolf IG, Reinhardt M, Ezziddin S, et al. Repeated bone-targeted therapy for hormone-refractory prostate carcinoma: randomized phase II trial with the new, high-energy radiopharmaceutical rhenium-188 hydroxyethylidenediphosphonate. J Clin Oncol 2003;21(15):2869-2875
17. Deutsch E, Libson K, Vanderheyden JL, Ketring AR, Maxon HR. The chemistry of rhenium and technetium as related to the use of isotopes of these elements in therapeutic and diagnostic nuclear medicine. Int J Rad Appl Instrum B 1986;13(4):465-477
18. Mathieu L, Chevalier P, Galy G, Berger M. Preparation of rhenium-186 labelled EHDP and its possible use in the treatment of osseous neoplasms. Int J Appl Radiat Isot 1979;30(12):725-727
19. Maxon HR 3rd, Schroder LE, Hertzberg VS, Thomas SR, Englaro EE, Samaratunga R, et al. Rhenium-186(Sn)HEDP for treatment of painful osseous metastases: results of a double-blind crossover comparison with placebo. J Nucl Med 1991;32(10):1877-1881
20. Maxon HR 3rd, Schroder LE, Thomas SR, Hertzberg VS, Deutsch EA, Scher HI, et al. Re-186(Sn) HEDP for treatment of painful osseous metastases: initial clinical experience in 20 patients with hormone-resistant prostate cancer. Radiology 1990;176(1):155-159
21. de Klerk JM, van het Schip AD, Zonnenberg BA, van Dijk A, Stokkel MP, Han SH, et al. Evaluation of thrombocytopenia in patients treated with rhenium-186-HEDP: guidelines for individual dosage recommendations. J Nucl Med 1994;35(9):1423-1428
22. de Klerk JM, van Dijk A, van het Schip AD, Zonnenberg BA, van Rijk PP. Pharmacokinetics of rhenium-186 after administration of rhenium-186-HEDP to patients with bone metastases. J Nucl Med 1992;33(5):646-651
23. O'Sullivan JM, McCready VR, Flux G, Norman AR, Buffa FM, Chittenden S, et al. High activity rhenium-186 HEDP with autologous peripheral blood stem cell rescue: a phase I study in progressive hormone refractory prostate cancer metastatic to bone. Br J Cancer 2002;86(11):1715-1720
24. Bubley GJ, Carducci M, Dahut W, Dawson N, Daliani D, Eisenberger M, et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 1999;17(11):3461-3467
25. Graham C, Bond SS, Gerkovich MM, Cook MR. Use of the McGill pain questionnaire in the assessment of cancer pain: replicability and consistency. Pain 1980;8(3):377-387
26. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993;85(5):365-376
27. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351(15):1502-1512
28. Shah RB, Mehra R, Chinnaiyan AM, Shen R, Ghosh D, Zhou M, et al. Androgen-independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program. Cancer Res 2004;64(24):9209-9216
29. Quilty PM, Kirk D, Bolger JJ, Dearnaley DP, Lewington VJ, Mason MD, et al. A comparison of the palliative effects of strontium-89 and external beam radiotherapy in metastatic prostate cancer. Radiother Oncol 1994;31(1):33-40
30. 186Re-HEDP treatment of skeletal metastases from prostate cancer. Eur J Nucl Med Mol Imaging 2003;30(8):1114-1124
31. Yarnold JR, Horwich A, Duchesne G, Westbrook K, Gibbs JE, Peckham MJ. Chemotherapy and radiotherapy for advanced testicular non-seminoma. I. The influence of sequence and timing of drugs and radiation on the appearance of normal tissue damage. Radiother Oncol 1983;1(2):91-99
32. Looney WB. Alternating chemotherapy and radiotherapy. NCI Monogr 1988;6(6):85-94
33. Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002;94(19):1458-1468
34. Dearnaley DP, Sydes MR, Mason MD, Stott M, Powell CS, Robinson AC, et al. A double-blind, placebo-controlled, randomized trial of oral sodium clodronate for metastatic prostate cancer (MRC PR05 Trial). J Natl Cancer Inst 2003;95(17):1300-1311
35. Carducci MA, Padley RJ, Breul J, Vogelzang NJ, Zonnenberg BA, Daliani DD, et al. Effect of endothelin - a receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial. J Clin Oncol 2003;21(4):679-689